FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

著录项

• 来源
  《Journal of Antimicrobial Chemotherapy》 |2011年第3期|p.19-32|共14页
• 作者

  Thomas M. File Jr; Donald E. Low; Paul B. Eckburg; George H. Talbot; H. David Friedland; Jon Lee; Lily Llorens; Ian A. Critchley; Dirk A. Thye;

  展开▼
• 作者单位

  Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH, USA/Summa Health System, Akron, OH, USA;

  Mount Sinai Hospital/University Health Network, Toronto, Ontario, Canada;

  Cerexa, Inc., Oakland, CA, USA (a wholly owned subsidiary of Forest Laboratories, Inc., New York, NY, USA);

  Talbot Advisors, LLC, Wayne, PA, USA;

  Cerexa, Inc., Oakland, CA, USA (a wholly owned subsidiary of Forest Laboratories, Inc., New York, NY, USA);

  Cerexa, Inc., Oakland, CA, USA (a wholly owned subsidiary of Forest Laboratories, Inc., New York, NY, USA);

  Cerexa, Inc., Oakland, CA, USA (a wholly owned subsidiary of Forest Laboratories, Inc., New York, NY, USA);

  Cerexa, Inc., Oakland, CA, USA (a wholly owned subsidiary of Forest Laboratories, Inc., New York, NY, USA);

  Cerexa, Inc., Oakland, CA, USA (a wholly owned subsidiary of Forest Laboratories, Inc., New York, NY, USA);

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词